TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06197412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
Study: NCT05523141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC10
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner
Study: NCT05609942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-263
Description: BLU-263 Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-263
Description: BLU-263 Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
Study: NCT05313282

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
Description: Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib combined with Camrelizumab
Description: Drug: Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication 2. Intravenous infusion of Camrelizumab 200mg every 2 weeks.
Study: NCT05496608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD
Description: Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD
Description: Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: OFD
Description: Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CM
Description: Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects
Study: NCT05900817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antivet
Description: A material used for micro abrasion of teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oplsture
Description: A material used for micro abrasion of teeth
Study: NCT05237284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT05738122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60-Day self-guided Emotion Regulation Journal
Description: A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
Study: NCT05493813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive function and delirium evaluation
Description: Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive function and delirium evaluation
Description: Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurological functional assessment
Description: National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurological functional assessment
Description: National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
Study: NCT06384456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TRanexamic Acid
Description: 10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
Study: NCT05577910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vectored thermal pulsation (VTP) therapy
Description: VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light with meibomian gland expression (IPL+MGX) therapy
Description: IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid Warm Compress Therapy (EW)
Description: EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical eye drops (Hypromellose, 3mg/ml)
Description: All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical eye drops (Hypromellose, 3mg/ml)
Description: All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical eye drops (Hypromellose, 3mg/ml)
Description: All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
Study: NCT05821972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulization of dexmedetomidine and ketamine
Description: Pre-operative nebulization of dexmedetomidine and ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulization of dexmedetomidine
Description: Pre-operative nebulization of dexmedetomidine
Study: NCT06293105

Intervention type: OTHER
Intervention: Qualitative interview, participant observation
Description: Qualitative in-depth interviews to explore experiences of and perspectives on stigma and discrimination, linked to being present in settings where there is participant observation

Intervention type: OTHER
Intervention: Qualitative interview, participant observation
Description: Qualitative in-depth interviews to explore experiences of and perspectives on stigma and discrimination, linked to being present in settings where there is participant observation
Study: NCT04493151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem, Cilastatin and Relebactam
Description: After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
Study: NCT04861194

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neurovascular-sparing
Description: Dose reduction of the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb during 5x7.25 Gy MRgRT
Study: NCT05876793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.Successful sedation results in a positive reaction, while failure results in a negative reaction. This study ends when 7 positive and negative reactions intersect
Study: NCT05919095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrilizumab plus GEMOX
Description: PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment.
Study: NCT06646510

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional exercises
Description: strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercises
Description: strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory electrical stimulation
Description: The stimulated muscles included the flexor carpi radialis (FCR), extensor carpi radialis (ECR), and flexor carpi ulnaris (FCU). Rectangular surface electrodes (Ag/AgCl; 50mm _ 50mm size) were attached on the motor point of each muscle, i.e., at four fingerbreadths from biceps tendon of FCR, at two fingerbreadths distal from lateral epicondyle for the ECR, at two fingerbreadths volar to ulna at the junction of the upper and middle thirds of the forearm for FCU.14 Portable stimulators will use with the following stimulation settings: constant current (0.2 mA step), 100 Hz stimulation frequency, biphasic pulse, and 300 _s pulsewidth.
Study: NCT04912388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbal stabilization excercises
Description: The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercises
Description: The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
Study: NCT06649279

Intervention type: DEVICE
Intervention: Oxygen reserve index
Description: Measuring oxygen reserve index during preoxygenation and under general anesthesia

Intervention type: DEVICE
Intervention: Oxygen reserve index
Description: Measuring oxygen reserve index during preoxygenation and under general anesthesia
Study: NCT06648902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meldonium
Description: 500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meldonium
Description: 500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meldonium
Description: 500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6
Study: NCT06648525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposomes
Description: Irinotecan liposomes, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposomes
Description: Irinotecan liposomes, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-Fluorouracil (5-FU), IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-Fluorouracil (5-FU), IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: Calcium folinate, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: Calcium folinate, IV
Study: NCT06649032

Intervention type: OTHER
Intervention: No intervention
Description: no difference: both cohorts are followed in the same way

Intervention type: OTHER
Intervention: No intervention
Description: no difference: both cohorts are followed in the same way
Study: NCT05141643

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of \[18F\]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second \[18F\]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
Study: NCT06559852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants will engage in a 12-week virtual yoga course to assess impact on endometriosis-related pain
Study: NCT05625191

Intervention type: DIAGNOSTIC_TEST
Intervention: Acoustic voice analysis
Description: Acoustic recordings will involve the five repetitions of three vowels (/ɑ, i, u/) and a standard reading passage (Rainbow Passage) in different voice conditions. Control participants will produce voice in breathy, typical, and pressed conditions. Patient participants will produce voice in typical production and in a resonant voice production. High-speed videoendoscopy and simultaneous acoustic recording will occur on one repetition of a sustained /i/ in each requested condition. Data will be collected using a head-mounted microphone.

Intervention type: DIAGNOSTIC_TEST
Intervention: High-speed videoendoscopy
Description: High-speed videoendoscopy will occur on one repetition of a sustained /i/ in each requested condition. Exams will be recorded using the Phantom V311 high-speed camera (Vision Research, Wayne, NJ) connected to a Storz 70° rigid laryngoscope using a 400 Watt Xenon light source (Titan 400E).
Study: NCT05605639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (physiological saline serum infiltration)
Description: The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
Study: NCT04242992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA
Description: CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short Message Service (SMS) text reminders
Description: Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) text reminders
Description: Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
Study: NCT06649227

Intervention type: DRUG
Group type: OTHER
Intervention: CAR-T cell therapy
Description: cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.
Study: NCT04658706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A supervised exercise program
Description: is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A supervised exercise program
Description: is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: exercise prescription
Description: they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
Study: NCT05074446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stereotype threat manipulation
Description: Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs.~Stereotype threat manipulation will be performed on the intensivist and non-intensivist participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare the cardiopulmonary resuscitation performance between intensive care units and other branches. The other participants (Control Group) will not be given any prior information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stereotype threat manipulation
Description: Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs.~Stereotype threat manipulation will be performed on the intensivist and non-intensivist participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare the cardiopulmonary resuscitation performance between intensive care units and other branches. The other participants (Control Group) will not be given any prior information.
Study: NCT06079307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygenated Mouthwash
Description: Will be comparing the impact of using oxygenated mouthwash with other groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygenated mouth foam
Description: will be comparing the impact of using oxygenated foam to other groups.